ClinicalTrials.gg
Not yet recruitingNCT04790045LymBIOUpdated Oct 3, 2023

Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens

A Phase 4 interventional study of Venetoclax in Chronic Lymphocytic Leukemia, sponsored by Paolo Ghia. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-03.

Sponsored by Paolo Ghia · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell — 21 open to participants now, 42 under way, 8 of them phase 3. venetoclax · Leukemia, Lymphocytic, Chronic, B-Cell.

Planned enrollment
55th of 69
30 · median 72
Started
2023
with 3 others
Phase 4
Only one
of the 69
Primary completion
2026-12
later than 14 of 41 live
Registered
48th of 69
by date
Lead sponsor
3 of 69
Paolo Ghia

Among the 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 55th largest by planned enrollment, is one of 4 that started in 2023, is the only one in phase 4, reaches primary completion later than 14 of the 41 other live ones, and was the 48th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,039 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

21 of the 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

CLL subjects who should receive treatment with a venetoclax-based regimen as per standard of care will be enrolled into this trial, after providing informed consent.

The following evaluations will be performed baseline before starting treatment:

Baseline assessments:

In addition to standard staging procedures before treatment initiation, including blood tests and BM aspirate and biopsy, the following procedures will be performed per protocol:

  • Peripheral blood sample drawing for pharmacodynamics studies, MRD assessment and cfDNA evaluation
  • Ultrasound-guided lymph node CNB
  • Tailored ultrasound evaluation of nodal sites and spleen
  • Bone marrow MRD sample drawing (optional) The nodal site for the biopsy will be selected based on the size (the largest nodal lesion will be considered) and the procedure feasibility (only superficial cervical, axillary or inguinal lymph nodes will be considered suitable for biopsy).

On treatment assessments:

Peripheral blood sampling and ultrasound-guided lymph node CNB will be repeated in patients on venetoclax-based therapy:

  • 7 days after completion of venetoclax ramp up phase,
  • +12 months after completion of venetoclax ramp-up phase. Patients with residual lymph nodes that are not suitable for ultrasound-guided lymph node CNB will continue the ultrasound monitoring only

Patients will follow an intensive ultrasound monitoring schedule, which requires tailored ultrasound evaluation being repeated at the following timepoints:

  • 4 weeks after venetoclax ramp-up completion
  • Every 2 months thereafter until disease progression or unacceptable toxicity leading to permanent treatment discontinuation.

Assessments at progression:

A tailored ultrasound of nodal sites and spleen will be performed within 2 weeks from the first signs and/or symptoms of suspected progression. US assessment can be delayed at Investigator's discretion in case pseudo-progression is suspected based on potentially confounding concomitant conditions, e.g. infection.

In progressive cases, the same assessments (including BM aspirate and biopsy) will be repeated at the time of disease progression.

In patients progressing with bulky lymph nodes an incisional lymph node biopsy (instead of an ultrasound-guided CNB) will be performed to exclude Richter's transformation as per standard of care.

Read the detailed description

LN, PB and BM mononuclear cells collected from CLL patients at specified timepoints will be tested by:

  • High-throughput ex vivo drug assay (2D platforms)
  • Global transcriptome analysis by RNA sequencing
  • Flow cytometry including activation and adhesion/migration markers, e.g. CD69, CD80, CD86, HLA-DR, CD38, CD49d, CXCR4;
  • Phospho-flow assays, to assess the phosphorylation state of proteins involved in BCR signaling transduction, e.g. AKT and ERK;
  • Western blot of nuclear lysates and cytoplasmic protein fractions to validate the expression of relevant genes
  • Targeted deep-sequencing by a previously validated panel

Minimal residual disease evaluation will be performed by:

  • 6-color flow cytometry
  • NGS CfDNA will be analysed by targeted NGS.

The following features will be evaluated by tailored ultrasound:

Superficial nodal sites (linear probe 7.5 MHz):

  • Site
  • Size: long and short diameter (sensitivity \<5 mm)
  • Shape
  • Border
  • echo-structure of the cortex; assessment of possible intranodal reticulation
  • Echogenic description of the hilum: presence, absence and irregular echo-morphology

Optional parameters:

  • Doppler evaluation: vascular distribution, vascular resistance
  • Contrast enhanced ultrasound (CEUS): 7.5 MHz linear probe (optional);Quantitative assessment with dedicated software (wash-in and wash-out curves): optional

Deep nodal sites (probe 3.5-5 MHz):

  • Site
  • Presence/absence of deep lymphoadenopathies
  • Size (sensitivity \<5 mm)
  • Echo-structure of the cortex (only if superficial, e.g. external iliac LN)

Optional parameters:

  • Vascular pattern by: color doppler, two-dimensional power doppler and MicroV (only if superficial, e.g. external iliac LN)
  • Contrast enhanced ultrasound (CEUS) (optional): vascular pattern present vs absent, intensity

Spleen:

  • Size (dedicated software to more precisely define the bipolar diameter) : in cm
  • Cross sectional area in cm2

Optional parameters:

  • Splenic artery resistive index
  • Portal vein flow (forward or non-forward portal flow): Vmax ("maximum velocity expressed in cm" and "mean Velocity expressed in cm")
  • Splenic stiffness (with Fibroscan or point share wave or share wave 2D) expressed in kPa

Liver:

  • Size
  • Echo-structure

Optional parameters:

  • Portal vein flow parameters
  • Liver artery resistive index
  • Liver stiffness expressed in kPa
03

Conditions studied

  • Chronic Lymphocytic Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • CLL diagnosis
  • Patients receiving treatment with venetoclax-based regimens
  • Baseline value >100x109/l
  • PT and aPTT within normal range

Exclusion criteria

Exclusion Criteria:

  • Patients receiving anticoagulant or antiplatelet treatment that cannot be safely interrupted before the
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Other
    Venetoclax-based treatment

    Single-arm study Patients enrolled will be receiving venetoclax-based regimens according to the standard of care

    Drug: Venetoclax

Interventions

  • Core-needle biopsy to be performed before starting treatment in patients candidates to venetoclax-based regimens

    Also known as: core-needle biopsy

06

What researchers measure

Primary outcomes

  1. To evaluate lymph node changes in CLL patients treated with venetoclax-based regimens both at molecular level

    Gene expression profile of CLL cells derived from lymph nodes of patients treated with venetoclax-based regimens

    Time frame: 24 months

  2. To evaluate lymph node changes in CLL patients treated with venetoclax-based regimens both at ultrasound level

    Ultrasound characteristics of lymph nodes of patients treated with venetoclax-based regimens

    Time frame: 24 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2023; primary completion for Dec 2026, 37 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2021
First posted
Mar 10, 2021
StartEst.
Nov 1, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Oct 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04790045
Lead sponsor
Paolo Ghia
Responsible party
Paolo Ghia (Director, IRCCS San Raffaele) — Sponsor-investigator
First posted
Mar 10, 2021
Start date
Nov 1, 2023 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 3, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venetoclax

Start the discussion